Eloralintide
ENLIGHTEN-4
Eli Lilly · Phase 3 · Recruiting · Enrollment 900
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Eloralintide (YOA1) | n/r | n/r | n/r | n/r | n/r |
| Placebo (YOA1) | n/r | n/r | n/r | n/r | n/r |
| Eloralintide (YOA2) | n/r | n/r | n/r | n/r | n/r |
| Placebo (YOA2) | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.